🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Proud of my research team presenting our work at #hfsa2023 @hfsa Cleveland Clinic Heart, Vascular & Thoracic Cleveland Clinic Lerner Research Institute

Two decades have gone by fast! Congrats Randall Starling on receiving the #hfsa2023 Lifetime Achievement Award. Josef Stehlik Cleveland Clinic Heart, Vascular & Thoracic @hfsa

Emerging insights into the pathophysiologic basis, mode action and proof of concept features of renal assist devices in acute decompensated heart failure: bit.ly/3Q1AQjw #JACCHF #HeartFailure Pieter Martens W. H. Wilson Tang, MD

This phase 3 trial of patisiran, a small interfering RNA that targets hepatic production of the transthyretin protein, showed efficacy in treating transthyretin-mediated (ATTR) cardiac amyloidosis. Read the full APOLLO-B trial results: nej.md/4081o7o

Prognostic Value of Natriuretic Peptide Levels for Adverse Renal Outcomes in Patients With Moderate to Severe Acute Kidney Injury With or Without Heart Failure. #AHAJournals W. H. Wilson Tang, MD ahajrnls.org/40J9bcl

News in EHJ: Promises and challenges of targeting anti-CXCR3 autoantibodies in cardiovascular disease! academic.oup.com/eurheartj/adva… #cardioprotective #therapy #autoantibodies #G-protein #receptors #cardiotwitter European Society of Cardiology @ESC_journals

#CVCT2023 #JACCHF SimPub: Meta-analysis of all randomized controlled trials in #HeartFailure. IV iron reduces both CV-death and HF-readmissions. But it might be time to redefine our definition of iron deficiency based on TSAT. bit.ly/3N5qfU4 CVCT - CardioVascular Clinical Trialists Pieter Martens

🚨 Act Fast! 🕒 Deadlines for #THT2024 Call for Science are right around the corner! 👉 Submit abstracts, fellows abstracts, fellows challenging cases, and THT Shark Tank Innovation Competition by Dec. 4, 2PM ET. 👉 Submit late-breaking clinical science/first-in-human and early

Q: Is intravenous iron beneficial for patients with #heartfailure and iron deficiency? A: In patients with HF and iron deficiency, treatment with IV iron can reduce CV deaths and HF hospitalizations. bit.ly/4aL4MKs #JACCHF

The MF is thrilled to announce one of the 2023 Fellowship Grant recipients, Dr. Simon Vanhentenrijk, MD, Pharm D, of the Cleveland Clinic! Read about his work below. myocarditisfoundation.org/the-myocarditi…

So incredibly proud of Cleveland Clinic representation at #CMR2024 in London Society for Cardiovascular Magnetic Resonance. 14 oral presentations and a ECA finalist. Celebrating at last night’s dinner! @ATandonMD DebbieKwonMD Cardiovascular Innovation Research Center CCF HVTI Cleveland Clinic Heart, Vascular & Thoracic @CleClinicLCM

The new #JACCHF issue is now out! Hemodynamic gain index and peak rate pressure product can identify patients w/ #HFrEF at risk of poor clinical outcomes. This allows prognostication of #HeartFailure even when CPET is not available. bit.ly/49p3hjk #CHF W. H. Wilson Tang, MD

Niacin, the B vitamin that was previously used to improve lipid profile and reduce the risk of heart disease, promotes arterial inflammation and cardiovascular risk through its metabolites nature.com/articles/s4159… Nature Medicine

Great start with our fearless leader Dan Burkhoff MD PhD kicking off exciting #THT2024 with 3 days of packed agenda and exciting discussions in #heartfailure innovations.

#Perspective: Unraveling the Complex Relationship Between Gut Microbiome and Cardiovascular Diseases Cleveland Clinic Lerner Research Institute W. H. Wilson Tang, MD ahajournals.org/doi/10.1161/CI…

🆕statement on evaluating & managing kidney dysfunction in patients with advanced heart failure. 📷Approach to assessment of kidney dysfunction in advanced HF ✍🏼@nishakidneydoc W. H. Wilson Tang, MD Janani Rangaswami Amy G. Fiedler, MD Modele Ogunniyi, MD, MPH @PietermartensMD James Fang Xingxing Cheng, MD MS @mbakitas

🚨 Final Call: Secure Your Discounted Room by January 22! Stay at the Omni Boston Hotel at the Seaport, the official #THT2025 venue. Rooms are limited — don’t wait! ✅ Registered attendees, use the reservation link in your confirmation email to secure your spot (subject to

Official kickoff of #THT2025 with #heartfailure innovations by Dan Burkhoff MD PhD TCTMD HFSA

From the CABANA trial: Patients with #HFpEF benefited even more from #Afib ablation regarding: 🔸Death/CV 🏥 🔸AF recurrence Despite the greater benefit for HFpEF pts, their risk of recurrence remained ⬆️ than in those w/out HFpEF 📎: jacc.org/doi/10.1016/j.… #JACCHF